No Data
No Data
Crinetics Pharmaceuticals Strengthens Leadership With New Appointment
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Express News | Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Press Release: Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $87